Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
23,100
0.00 (0.00%)
Aug 8, 2025, 3:30 PM KST
Market Cap486.70B
Revenue (ttm)20.89B
Net Income (ttm)-12.21B
Shares Out21.07M
EPS (ttm)-952.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume85,451
Average Volume172,211
Open23,100
Previous Close23,100
Day's Range22,500 - 23,400
52-Week Range15,950 - 42,250
Betan/a
RSI57.32
Earnings DateAug 14, 2025

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company focuses on degrader-antibody conjugate that combine antibody-drug conjugate with targeted protein degradation technology. Its lead product candidate is ORM-1153, a GSPT1 protein degrader that targets hematologic malignancies. The company was founded in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 20
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.